A Clinical Trial to test a turmeric based product (Curenext) in treating gum disease.

Assessment of Interleukin 1β levels and clinical effects of curcumin gel in an experimental gingivitis model. A randomized double blind placebo controlled clinical trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/05/001767

Enrollment

Registered

2011-05-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Gingivitis

Interventions

Intervention1: Curcumin: Topical agent on gums. One centimeter of the agent expressed from the provided tube to be applied on the gums and rubbed for a minute, twice a day. Dose of product as per manu

Eligibility

Inclusion criteria

Inclusion criteria: Systemically healthy adults between 20 and 24 years of age with healthy periodontium (no sites with 2mm of probing depth.

Exclusion criteria

Exclusion criteria: Pregnancy, on antibiotics, on antiinflammatory drugs.

Design outcomes

Primary

Measure	Time frame
Interleukin 1 Beta levels in gingival crevicular fluid after application of test and control in an experimental gingivitis model.Timepoint: 8th day	—

Secondary

Measure	Time frame
Clinical healing. Bleeding indexTimepoint: 8th day	—

Countries

India

Contacts

Public ContactShaju Jacob P

Chhattisgarh Dental College and Research Institute

shajujacob@yahoo.com9893490795

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026